CY1124316T1 - Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα - Google Patents

Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Info

Publication number
CY1124316T1
CY1124316T1 CY20211100652T CY211100652T CY1124316T1 CY 1124316 T1 CY1124316 T1 CY 1124316T1 CY 20211100652 T CY20211100652 T CY 20211100652T CY 211100652 T CY211100652 T CY 211100652T CY 1124316 T1 CY1124316 T1 CY 1124316T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparations
pi3k delta
selective inhibitor
tosylate salt
crystalline tosylate
Prior art date
Application number
CY20211100652T
Other languages
Greek (el)
English (en)
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of CY1124316T1 publication Critical patent/CY1124316T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20211100652T 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα CY1124316T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1124316T1 true CY1124316T1 (el) 2022-07-22

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100652T CY1124316T1 (el) 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Country Status (22)

Country Link
US (4) US9969740B2 (OSRAM)
EP (2) EP3149000B1 (OSRAM)
JP (3) JP6987501B2 (OSRAM)
KR (1) KR20170007480A (OSRAM)
CN (2) CN106661030B (OSRAM)
AU (1) AU2015265542B2 (OSRAM)
BR (1) BR112016027674A2 (OSRAM)
CA (1) CA2949932C (OSRAM)
CY (1) CY1124316T1 (OSRAM)
DK (1) DK3149000T3 (OSRAM)
EA (1) EA032506B1 (OSRAM)
ES (1) ES2880999T3 (OSRAM)
HR (1) HRP20211151T1 (OSRAM)
HU (1) HUE054916T2 (OSRAM)
IL (1) IL249058B2 (OSRAM)
LT (1) LT3149000T (OSRAM)
PL (1) PL3149000T3 (OSRAM)
PT (1) PT3149000T (OSRAM)
RS (1) RS62136B1 (OSRAM)
SI (1) SI3149000T1 (OSRAM)
SM (1) SMT202100532T1 (OSRAM)
WO (1) WO2015181728A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
US20190247399A1 (en) 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2021009509A1 (en) 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
LT2870157T (lt) 2012-07-04 2017-12-11 Rhizen Pharmaceuticals S.A. Selektyvieji pi3k delta inhibitoriai
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche

Also Published As

Publication number Publication date
IL249058B2 (en) 2023-03-01
EP3149000A1 (en) 2017-04-05
PL3149000T3 (pl) 2021-11-02
BR112016027674A2 (pt) 2017-08-15
AU2015265542B2 (en) 2019-05-09
RS62136B1 (sr) 2021-08-31
KR20170007480A (ko) 2017-01-18
AU2015265542A1 (en) 2016-12-08
US20170121336A1 (en) 2017-05-04
US20190016725A1 (en) 2019-01-17
DK3149000T3 (da) 2021-08-30
ES2880999T3 (es) 2021-11-26
JP2020122022A (ja) 2020-08-13
US9969740B2 (en) 2018-05-15
US20190382411A1 (en) 2019-12-19
CN106661030B (zh) 2020-06-30
LT3149000T (lt) 2021-09-10
HUE054916T2 (hu) 2021-10-28
US20210269446A1 (en) 2021-09-02
WO2015181728A1 (en) 2015-12-03
IL249058A0 (en) 2017-01-31
JP2017516785A (ja) 2017-06-22
IL249058B (en) 2022-11-01
JP6987501B2 (ja) 2022-01-05
EA201692255A1 (ru) 2017-04-28
PT3149000T (pt) 2021-07-27
SI3149000T1 (sl) 2021-09-30
SMT202100532T1 (it) 2021-11-12
US10414773B2 (en) 2019-09-17
EP3149000B1 (en) 2021-06-30
CA2949932C (en) 2021-08-10
JP2022082680A (ja) 2022-06-02
HRP20211151T1 (hr) 2021-10-15
EA032506B1 (ru) 2019-06-28
CN111635406A (zh) 2020-09-08
CA2949932A1 (en) 2015-12-03
US10947244B2 (en) 2021-03-16
CN106661030A (zh) 2017-05-10
EP3971188A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
CY1124316T1 (el) Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201792116A1 (ru) Ингибитор янус-киназы
DOP2015000189A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич